Genomic Study of Genetic Polymorphisms Involved in Immediate Allergic Reactions to Beta-lactam Antibiotics (PANGENOMIC-BL)
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT02895646|
Recruitment Status : Unknown
Verified September 2016 by Central Hospital, Nancy, France.
Recruitment status was: Active, not recruiting
First Posted : September 12, 2016
Last Update Posted : February 3, 2017
Beta-lactam antibiotics include penicillin and cephalosporins and are among the most prescribed antibiotics. This category of drugs is the most involved in immediate allergic manifestations with 2% reactions in treated subjects and a fatal outcome in 1/50000 treatments. Reactions are IgE-mediated and have a considerable but unknown genetic origin, revealed by studies in groups of different ethnical origins in the same geographical region. There are also some families with a high frequency of allergic reactions without identified Mendelian inheritance.
The purpose of this study is to identify predictive risk factors associated to immediate allergic reactions against beta-lactam antibiotics with a pangenomic approach.
A secondary purpose is to identify rare predictive factors with homozygosity mapping and exome sequencing in various families with high risk of allergy to beta-lactam antibiotics.
|Condition or disease||Intervention/treatment|
|Beta-Lactams Allergy Hypersensitivity||Other: Collection of blood sample|
|Study Type :||Observational|
|Actual Enrollment :||2356 participants|
|Official Title:||Genomic Study of Genetic Polymorphisms Involved in Immediate Allergic Reactions to Beta-lactam Antibiotics|
|Study Start Date :||June 2012|
|Estimated Primary Completion Date :||June 2017|
|Estimated Study Completion Date :||June 2017|
Beta-lactam antibiotic allergy
Diagnosis based on clinical symptomatology and skin test positive for allergen and negative for other drugs and substances. Skin tests are performed 6 weeks after allergic reaction.
Other: Collection of blood sample
No specific clinical investigation for control subjects
Other: Collection of blood sample
- Analysis of genetic polymorphisms predictive of risk of beta-lactam immediate allergy [ Time Frame: day 0 ]Common (>10%) or rare (1-10%) genetic polymorphisms in patients with beta-lactam immediate allergy
- Analysis of allelic homozygosity linked to allergen response, in more than 2 allergic individuals of the same family [ Time Frame: day 0 ]Allelic homozygosity in one or more regions of genome with one or more genes involved in allergen response, in more than 2 individuals affected by beta-lactam allergy in the same family
- Severity of allergic reaction [ Time Frame: day 0 ]evaluated during clinical examination
- Reactivity to skin test [ Time Frame: day 0 ]
- Serum concentration of specific IgE [ Time Frame: day 0 ]
Biospecimen Retention: Samples With DNA
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02895646
|Principal Investigator:||Jean-Louis GUEANT||Service de BBMNM, CHU Nancy / unité INSERM U954, Faculté de Médecine, 54500 Vandoeuvre Les Nancy|